Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, character- In line with this, anti-collagen antibody levels were significantly reduced in CCR6 −/− mice compared with WT mice. Moreover, we demonstrate enhanced osteoclastogenesis in vitro in CCR6 −/− mice compared with WT mice. However, we did not detect differences in bone mass under steady state conditions in vivo between WT and CCR6-deficient mice. These data suggest that CCR6 is crucially involved in adaptive but not in innate immunity-driven arthritis. CCR6 or its chemokine ligand CCL20 might represent a possible new target for the treatment of RA.
Migration of inflammatory cells is mediated by a set of receptors which respond to environmental cues and direct the migration of inflammatory cells to the site of inflammation. Among them, the chemokine receptor 6 (CCR6) has been demonstrated to be expressed on a number of cell types important in the pathogenesis of inflammatory arthritis. CCR6 has been shown to characterize a subset of CD4 + T cells, the IL-17-producing Th17 cells. 1,2 CCR6 + T cells have been detected in the inflamed synovium and the peripheral blood of RA patients. [3] [4] [5] [6] CCR6 + effector T cells can produce various cytokines like IL-17A, IL-17F, IL-22, IL-26, TNF-α, IFN or GM-CSF and therefore contribute to the development of RA by activation of monocytes, neutrophils, synovial fibroblasts and osteoclast differentiation. 7, 8 The ligand for CCR6, CCL20, is highly expressed at sites of inflammation, including the inflamed synovium of RA patients and therefore promotes the recruitment of CCR6-positive cells. [9] [10] [11] In T cell-driven experimental arthritis models as well as in patients with RA, the CCR6/CCL20 axis has convincingly been shown to promote the recruitment of Th17 cells into the inflamed synovial membrane.
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In addition to Th17 cells, CCR6 is also expressed on memory B cells and therefore might contribute to the migration of this cell population. 12 CCR6 was also found on activated antigen-specific B cells.
Moreover, CCR6 has also been shown to be expressed on innate immune cells, including dendritic cells, granulocytes, macrophages and NK cells. [13] [14] [15] [16] [17] [18] CCR6 was also expressed on infiltrating mononuclear cells in the synovium of RA patients. 19 In patients with RA, CCR6 expression on monocytes has been shown to correlate with the potential of monocytes to differentiate into osteoclasts ex vivo, suggesting a possible role of CCR6 on monocytes in the recruitment of osteoclast precursors to the joint. 20 However, despite the evidence for the importance of CCR6 in various cell types, which are known drivers for the development of RA, the role of CCR6 in the development of arthritis beyond T celldependent mechanisms has not been addressed. In this study, we therefore studied the effect of CCR6 deficiency in three different models of experimental arthritis, each with distinct, non-overlapping pathomechanisms. Assessments were performed in a blinded fashion. Animals were killed between week 3 and week 10 after disease induction. 
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Key messages
• CCR6 affects the development of CIA
• CCR6 is not involved in the TNF transgenic or serum transfer arthritis model
• CCR6 is involved in adaptive but not in innate immunitydriven arthritis.
BONELLI ET AL.
| 5279
Austria) as substrate. The OD was measured at 405 nm using a microplate reader (Titertek, Huntsville, AL). The quantity of specific antibody was measured for each animal, and data are expressed as mean relative units of activity based on a standard anti-CII serum that was generated from pooled sera of arthritic mice. Antibody values >0.15 units/mL were considered as positive.
| Induction of serum transfer arthritis
After intraperitoneal application of 150 μL of K/BxN serum on day 1
and day 3, mice were killed on day 12 to prepare tissue samples for histology.
| Evaluation of inflammation and local bone erosions by histological examination
Hind paws were fixed in formalin overnight and then decalcified in EDTA until the bones were pliable. Serial paraffin sections (2 μm)
were stained with haematoxylin and eosin (H&E) or stained for tartrate-resistant acid phosphatase (TRAP) activity. TRAP staining was performed using a leucocyte acid phosphatase staining kit (Sigma).
For exact quantification of the areas of inflammation, H&E-stained sections were evaluated using an Axioskop 2 microscope (Carl Zeiss
Micro-Imaging, Oberkochen, Germany) and Osteomeasure Analysis System (OsteoMetrics), which allows absolute quantification of areas in histological sections. The sum of the areas of inflammation for each single mouse was calculated by evaluating all tarsal joints. The same haematoxylin and eosin -stained sections were analysed similarly for the quantification of erosions. In addition, the number of osteoclasts was counted in TRAP-stained serial sections.
| In vitro osteoclast assay
Bone marrow cells were isolated from WT and CCR6 −/− mice and cultured for 3 days in 100 ng/mL macrophage colony-stimulating factor (M-CSF) to enrich for monocyte/macrophages and were then cultured in 10% FCS/Dulbecco's modified Eagle's medium supplemented with 30 ng/mL M-CSF and 50 ng/mL RANKL (both from R&D Systems) for another 3-4 days. Osteoclasts were detected by the presence of TRAP+ multinucleated cells (>3 nuclei).
| Statistical analysis
The unpaired t test was used to test statistically significant differences. A P-value less than or equal to 0.05 was considered significant. Data were analysed for Gaussian distribution.
| RESULTS
| Deletion of CCR6 reduces the development of arthritis in the collagen-induced arthritis model
To address the role of CCR6 in arthritis, we first analysed WT and 
| DISCUSSION
Previous studies have demonstrated CCR6 expression on a variety of cell types from the innate and adaptive immune system, which has been shown to be involved in the development of RA. The importance of CCR6 was further highlighted by GWAS studies, which have described a polymorphism of CCR6 in patients with RA. [22] [23] [24] [25] [26] Moreover, an involvement of CCR6 in RA is further substantiated by the finding of elevated CCL20 levels in the joints of RA patients as compared to patients with osteoarthritis. | 5283 stimulation compared to WT macrophages, suggesting that CCR6 might also be involved in the regulation of cytokine production in response to inflammatory stimuli. 20 Therefore, a direct comparison to our murine dataset is not possible. In conclusion, our data highlight for the first time the importance of CCR6 as part of the adaptive immune system for the development of arthritis, with no evidence of CCR6 being involved in innate immunity-driven arthritis. These findings therefore identify the CCR6/CCL20 axis as a potential new target for the treatment of patients with seropositive RA.
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